Glioblastoma adaptive global innovative learning environment

Glioblastoma adaptive  global  innovative learning environment
Recruiting
18 years - 99 years
All
Phase 2
10 participants needed
1 Location

Brief description of study

This research study aims to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. The investigational drugs that will be used in this research study are temozolomide for newly diagnosed glioblastoma and Lomustine for recurrent glioblastomas.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Glioblastoma
  • Age: 18 years - 99 years
  • Gender: All


Updated on 19 Feb 2024. Study ID: 834751

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.